A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Kim, Won Seog | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Chae, Yee Soo | - |
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Eom, Hyeon Seok | - |
dc.contributor.author | Ryoo, Hun Mo | - |
dc.contributor.author | Lee, Suee | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Yoon, Dok Hyun | - |
dc.contributor.author | Won, Jong Ho | - |
dc.contributor.author | Hong, Junshik | - |
dc.contributor.author | Park, Jinny | - |
dc.contributor.author | Lee, Sang-Min | - |
dc.contributor.author | Hong, Jung Yong | - |
dc.contributor.author | Park, Eunkyung | - |
dc.contributor.author | Kim, Hyo Jung | - |
dc.contributor.author | Yang, Deok-Hwan | - |
dc.contributor.author | Kim, Hyo-Jin | - |
dc.contributor.author | Suh, Cheolwon | - |
dc.date.available | 2020-02-28T01:44:17Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 1042-8194 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/8194 | - |
dc.description.abstract | Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130mg/m(2) on day 1 and prednisone 100mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range=27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate=64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI=2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.relation.isPartOf | LEUKEMIA & LYMPHOMA | - |
dc.subject | NON-HODGKIN-LYMPHOMA | - |
dc.subject | B-CELL LYMPHOMA | - |
dc.subject | TISSUE LYMPHOMA | - |
dc.subject | PRETREATED PATIENTS | - |
dc.subject | PLUS RITUXIMAB | - |
dc.subject | MALT LYMPHOMAS | - |
dc.subject | INDOLENT | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | BENDAMUSTINE | - |
dc.subject | CHLORAMBUCIL | - |
dc.title | A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000375129200023 | - |
dc.identifier.doi | 10.3109/10428194.2015.1099650 | - |
dc.identifier.bibliographicCitation | LEUKEMIA & LYMPHOMA, v.57, no.6, pp.1406 - 1412 | - |
dc.identifier.scopusid | 2-s2.0-84946949637 | - |
dc.citation.endPage | 1412 | - |
dc.citation.startPage | 1406 | - |
dc.citation.title | LEUKEMIA & LYMPHOMA | - |
dc.citation.volume | 57 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Park, Jinny | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Oxaliplatin | - |
dc.subject.keywordAuthor | prednisone | - |
dc.subject.keywordAuthor | relapse | - |
dc.subject.keywordAuthor | refractory | - |
dc.subject.keywordAuthor | marginal zone lymphoma | - |
dc.subject.keywordPlus | NON-HODGKIN-LYMPHOMA | - |
dc.subject.keywordPlus | B-CELL LYMPHOMA | - |
dc.subject.keywordPlus | TISSUE LYMPHOMA | - |
dc.subject.keywordPlus | PRETREATED PATIENTS | - |
dc.subject.keywordPlus | PLUS RITUXIMAB | - |
dc.subject.keywordPlus | MALT LYMPHOMAS | - |
dc.subject.keywordPlus | INDOLENT | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | BENDAMUSTINE | - |
dc.subject.keywordPlus | CHLORAMBUCIL | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.